Glucagonâ€like peptideâ€1 receptor activation stimulat hepatic signalling alteration induced by a highâ€fat diet

Liver International

31, 1285-1297

DOI: 10.1111/j.1478-3231.2011.02462.x

Citation Report

#	Article	IF	Citations
1	Glucagon likeâ€peptide 1 receptor and the liver. Liver International, 2011, 31, 1243-1245.	1.9	10
2	Acute activation of central GLP-1 receptors enhances hepatic insulin action and insulin secretion in high-fat-fed, insulin resistant mice. American Journal of Physiology - Endocrinology and Metabolism, 2012, 302, E334-E343.	1.8	65
3	Glucagon-like peptide-1 receptor agonism improves metabolic, biochemical, and histopathological indices of nonalcoholic steatohepatitis in mice. American Journal of Physiology - Renal Physiology, 2012, 302, G762-G772.	1.6	222
4	Incretin-based therapies for treatment of postprandial dyslipidemia in insulin-resistant states. Current Opinion in Lipidology, 2012, 23, 56-61.	1.2	36
5	When GLP-1 hits the liver: a novel approach for insulin resistance and NASH. American Journal of Physiology - Renal Physiology, 2012, 302, G759-G761.	1.6	33
6	Hepatic progenitor cells: Another piece in the nonalcoholic fatty liver disease puzzle. Hepatology, 2012, 56, 2013-2015.	3.6	8
7	Characterization of glucagon-like peptide 1 receptor (GLP1R) gene in chickens: functional analysis, tissue distribution, and identification of its transcript variants. Domestic Animal Endocrinology, 2012, 43, 1-15.	0.8	24
8	Cardiovascular Biology of the Incretin System. Endocrine Reviews, 2012, 33, 187-215.	8.9	468
9	Management of Non-alcoholic Fatty Liver Disease and Steatohepatitis. Journal of Clinical and Experimental Hepatology, 2012, 2, 156-173.	0.4	32
10	Role of Obesity and Lipotoxicity in the Development of Nonalcoholic Steatohepatitis: Pathophysiology and Clinical Implications. Gastroenterology, 2012, 142, 711-725.e6.	0.6	711
11	GLP-1 Receptor Activation Inhibits VLDL Production and Reverses Hepatic Steatosis by Decreasing Hepatic Lipogenesis in High-Fat-Fed APOE*3-Leiden Mice. PLoS ONE, 2012, 7, e49152.	1.1	71
12	GLP-1 Receptor Agonist and Non-Alcoholic Fatty Liver Disease. Diabetes and Metabolism Journal, 2012, 36, 262.	1.8	63
13	Evaluation of body fat composition after linagliptin treatment in a rat model of dietâ€induced obesity: a magnetic resonance spectroscopy study in comparison with sibutramine. Diabetes, Obesity and Metabolism, 2012, 14, 1050-1053.	2.2	9
14	Direct effect of GLP-1 infusion on endogenous glucose production in humans. Diabetologia, 2013, 56, 156-161.	2.9	117
15	Reply to: â€œDirect actions of GLP-1 analogues on AMP-activated protein kinase activity are distinct from cyclic AMP accumulationâ€. Journal of Hepatology, 2013, 58, 635-636.	1.8	0
16	Novel anti-diabetic agents in non-alcoholic fatty liver disease: a mini-review. Hepatobiliary and Pancreatic Diseases International, 2013, 12, 584-588.	0.6	23
17	Potential of incretin-based therapies for non-alcoholic fatty liver disease. Journal of Diabetes and Its Complications, 2013, 27, 401-406.	1.2	38
18	Pharmacological agents for nonalcoholic steatohepatitis. Hepatology International, 2013, 7, 833-841.	1.9	2

#	Article	IF	Citations
19	GLP-1 Receptor Activation Indirectly Reduces Hepatic Lipid Accumulation But Does Not Attenuate Development of Atherosclerosis in Diabetic Male ApoEâ^'/â^' Mice. Endocrinology, 2013, 154, 127-139.	1.4	288
20	Prebiotic approach alleviates hepatic steatosis: Implication of fatty acid oxidative and cholesterol synthesis pathways. Molecular Nutrition and Food Research, 2013, 57, 347-359.	1.5	90
21	Bile acid transporters and regulatory nuclear receptors in the liver and beyond. Journal of Hepatology, 2013, 58, 155-168.	1.8	304
22	Direct actions of GLP-1 analogues on AMP-activated protein kinase activity are distinct from cyclic AMP accumulation. Journal of Hepatology, 2013, 58, 634-635.	1.8	5
23	Eight weeks of treatment with long-acting GLP-1 analog taspoglutide improves postprandial insulin secretion and sensitivity in metformin-treated patients with type 2 diabetes. Metabolism: Clinical and Experimental, 2013, 62, 1330-1339.	1.5	12
24	Safety and efficacy of liraglutide in patients with type 2 diabetes and elevated liver enzymes: individual patient data metaâ€analysis of the LEAD program. Alimentary Pharmacology and Therapeutics, 2013, 37, 234-242.	1.9	204
25	Nonalcoholic Fatty Liver Disease: Current Issues and Novel Treatment Approaches. Drugs, 2013, 73, 1-14.	4.9	139
26	Nonalcoholic Fatty Liver Disease: A Novel Cardiometabolic Risk Factor for Type 2 Diabetes and Its Complications. Journal of Clinical Endocrinology and Metabolism, 2013, 98, 483-495.	1.8	259
27	Pharmacology, Physiology, and Mechanisms of Incretin Hormone Action. Cell Metabolism, 2013, 17, 819-837.	7.2	1,088
28	Effects of Sitagliptin on Nonalcoholic Fatty Liver Disease in Diet-Induced Obese Rats. Metabolic Syndrome and Related Disorders, 2013, 11, 243-250.	0.5	29
29	Induction of apolipoprotein A-I gene expression by glucagon-like peptide-1 and exendin-4 in hepatocytes but not intestinal cells. Metabolism: Clinical and Experimental, 2013, 62, 265-274.	1.5	14
30	Glucoseâ€dependent insulinotropic polypeptide and glucagonâ€like peptideâ€1: Incretin actions beyond the pancreas. Journal of Diabetes Investigation, 2013, 4, 108-130.	1.1	207
31	Liraglutide efficacy and action in non-alcoholic steatohepatitis (LEAN): study protocol for a phase II multicentre, double-blinded, randomised, controlled trial. BMJ Open, 2013, 3, e003995.	0.8	41
32	Diabetes and Nonalcoholic Fatty Liver Disease: A Pathogenic Duo. Endocrine Reviews, 2013, 34, 84-129.	8.9	197
33	Effects of intraportal exenatide on hepatic glucose metabolism in the conscious dog. American Journal of Physiology - Endocrinology and Metabolism, 2013, 305, E132-E139.	1.8	1
34	The Role of Gastrointestinal Hormones in Hepatic Lipid Metabolism. Seminars in Liver Disease, 2013, 33, 343-357.	1.8	63
35	GLP-1-derived nonapeptide GLP-1(28â€“36)amide represses hepatic gluconeogenic gene expression and improves pyruvate tolerance in high-fat diet-fed mice. American Journal of Physiology - Endocrinology and Metabolism, 2013, 305, E1348-E1358.	1.8	34
36	Multiple Hits, Including Oxidative Stress, as Pathogenesis and Treatment Target in Non-Alcoholic Steatohepatitis (NASH). International Journal of Molecular Sciences, 2013, 14, 20704-20728.	1.8	325

#	Article	IF	Citations
37	Role of thiazolidinediones, insulin sensitizers, in nonâ€alcoholic fatty liver disease. Journal of Diabetes Investigation, 2013, 4, 517-524.	1.1	37
38	Glucagon-like peptide-1 receptor activation reverses cardiac remodeling via normalizing cardiac steatosis and oxidative stress in type 2 diabetes. American Journal of Physiology - Heart and Circulatory Physiology, 2013, 305, H295-H304.	1.5	85
39	Ectopic fat: the true culprit linking obesity and cardiovascular disease?. Thrombosis and Haemostasis, 2013, 110, 651-660.	1.8	51
40	Pleiotropic Effects of an Incretin Hormone. Journal of Korean Diabetes, 2013, 14, 120.	0.1	0
41	Exenatide improves type 2 diabetes concomitant with non-alcoholic fatty liver disease. Arquivos Brasileiros De Endocrinologia E Metabologia, 2013, 57, 702-708.	1.3	93
42	AMPK, insulin resistance, and the metabolic syndrome. Journal of Clinical Investigation, 2013, 123, 2764-2772.	3.9	672
43	Non-alcoholic fatty liver disease and diabetes: From physiopathological interplay to diagnosis and treatment. World Journal of Gastroenterology, 2014, 20, 8377.	1.4	76
44	Glucose-Induced Glucagon-Like Peptide 1 Secretion Is Deficient in Patients with Non-Alcoholic Fatty Liver Disease. PLoS ONE, 2014, 9, e87488.	1.1	84
45	HCC Development Is Associated to Peripheral Insulin Resistance in a Mouse Model of NASH. PLoS ONE, 2014, 9, e97136.	1.1	76
46	GLP-1(28-36)amide, the Glucagon-like peptide-1 metabolite: friend, foe, or pharmacological folly?. Drug Design, Development and Therapy, 2014, 8, 677.	2.0	4
47	Pulmonary Arterial Hypertension and Insulin Resistance. Journal of Molecular and Genetic Medicine: an International Journal of Biomedical Research, 2014, 02, .	0.1	7
48	Pharmacologic Management of Non-Alcoholic Fatty Liver Disease. Advances in Pharmacoepidemiology & Drug Safety, 2014, 03, .	0.1	1
49	Molecular Mechanisms and New Treatment Strategies for Non-Alcoholic Steatohepatitis (NASH). International Journal of Molecular Sciences, 2014, 15, 7352-7379.	1.8	106
50	Exendin-4 Improves Nonalcoholic Fatty Liver Disease by Regulating Glucose Transporter 4 Expression in ob/ob Mice. Korean Journal of Physiology and Pharmacology, 2014, 18, 333.	0.6	23
51	GLP-1 receptor agonism ameliorates hepatic VLDL overproduction and de novo lipogenesis in insulin resistance. Molecular Metabolism, 2014, 3, 823-833.	3.0	66
52	Benefits of exenatide on obesity and nonâ€alcoholic fatty liver disease with elevated liver enzymes in patients with type 2 diabetes. Diabetes/Metabolism Research and Reviews, 2014, 30, 521-529.	1.7	144
53	Effect of Glucagon-Like Peptide 1 Receptor Agonists on Visceral Fat Adiposity, Appetite, and Food Preference. , 2014, , 167-176.		0
54	Insulin sensitizers for the treatment of non-alcoholic fatty liver disease. World Journal of Hepatology, 2014, 6, 199.	0.8	66

#	Article	IF	Citations
55	A direct comparison of longâ€•and shortâ€acting <scp>GLP</scp>â€1 receptor agonists (taspoglutide once) Tj ETQq0 0 0 rgBT /Overloc Obesity and Metabolism, 2014, 16, 170-178.	2.2	8
56	Nonalcoholic Fatty Liver Disease and Type 2 Diabetes in Obese Children. Current Diabetes Reports, 2014, 14, 448.	1.7	20
57	Linagliptin alleviates hepatic steatosis and inflammation in a mouse model of non-alcoholic steatohepatitis. Medical Molecular Morphology, 2014, 47, 137-149.	0.4	57
58	Exogenous glucagon-like peptide 1 reduces contractions in human colon circular muscle. Journal of Endocrinology, 2014, 221, 29-37.	1.2	37
59	Exendinâ€4 decreases liver inflammation and atherosclerosis development simultaneously by reducing macrophage infiltration. British Journal of Pharmacology, 2014, 171, 723-734.	2.7	95
60	Comparative analysis of plasma metabolomics response to metabolic challenge tests in healthy subjects and influence of the FTO obesity risk allele. Metabolomics, 2014, 10, 386-401.	1.4	16
61	Changes in post-prandial glucose and pancreatic hormones, and steady-state insulin and free fatty acids after gastric bypass surgery. Surgery for Obesity and Related Diseases, 2014, 10, 1-8.	1.0	36
62	The role of incretin-based therapies in prediabetes: A review. Primary Care Diabetes, 2014, 8, 286-294.	0.9	12
63	Differentially Regulated Protein Kinase A (PKA) Activity in Adipose Tissue and Liver Is Associated With Resistance to Diet-Induced Obesity and Glucose Intolerance in Mice That Lack PKA Regulatory Subunit Type IIÎ±. Endocrinology, 2014, 155, 3397-3408.	1.4	27
64	The effect of chronic twice daily exenatide treatment on Î²â€cell function in new onset type 2 diabetes. Clinical Endocrinology, 2014, 80, 545-553.	1.2	22
65	The cardiometabolic benefits of glycine: Is glycine an â€˜antidoteâ€™ to dietary fructose?. Open Heart, 2014, 1, e000103.	0.9	23
66	AMPK activation: a therapeutic target for type 2 diabetes?. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy, 2014, 7, 241.	1.1	214
67	Focus on emerging drugs for the treatment of patients with non-alcoholic fatty liver disease. World Journal of Gastroenterology, 2014, 20, 16841.	1.4	36
68	Exendin-4, a glucagon-like peptide-1 receptor agonist, modulates hepatic fatty acid composition and Î”-5-desaturase index in a murine model of non-alcoholic steatohepatitis. International Journal of Molecular Medicine, 2014, 34, 782-787.	1.8	20
69	Liraglutide reduces lipid accumulation in steatotic L-02 cells by enhancing autophagy. Molecular Medicine Reports, 2014, 10, 2351-2357.	1.1	32
70	Circulating dipeptidyl peptidaseâ€4 activity correlates with measures of hepatocyte apoptosis and fibrosis in nonâ€alcoholic fatty liver disease in type 2 diabetes mellitus and obesity: A dual cohort crossâ€sectional study. Journal of Diabetes, 2015, 7, 809-819.	0.8	44
71	The Glucagon-Like Peptide-1 Analogue Liraglutide Inhibits Oxidative Stress and Inflammatory Response in the Liver of Rats with Diet-Induced Non-alcoholic Fatty Liver Disease. Biological and Pharmaceutical Bulletin, 2015, 38, 694-702.	0.6	54
72	GLPâ€1 receptor agonists: effects on the progression of nonâ€alcoholic fatty liver disease. Diabetes/Metabolism Research and Reviews, 2015, 31, 329-335.	1.7	35

#	Article	IF	Citations
73	Exendinâ€4 attenuates brain deathâ€“induced liver damage in the rat. Liver Transplantation, 2015, 21, 1410-1418.	1.3	14
74	Bariatric surgery and nonalcoholic fatty liver disease. European Journal of Gastroenterology and Hepatology, 2015, 27, 755-768.	0.8	25
75	Glucagon Like Peptide-1 (GLP-1) Modulates OVA-Induced Airway Inflammation and Mucus Secretion Involving a Protein Kinase A (PKA)-Dependent Nuclear Factor-Î¹B (NF-Î¹B) Signaling Pathway in Mice. International Journal of Molecular Sciences, 2015, 16, 20195-20211.	1.8	71
76	The Dipeptidyl Peptidase-4 Inhibitor Teneligliptin Attenuates Hepatic Lipogenesis via AMPK Activation in Non-Alcoholic Fatty Liver Disease Model Mice. International Journal of Molecular Sciences, 2015, 16, 29207-29218.	1.8	41
77	Regulation of Pancreatic Î² Cell Mass by Cross-Interaction between CCAAT Enhancer Binding Protein Î² Induced by Endoplasmic Reticulum Stress and AMP-Activated Protein Kinase Activity. PLoS ONE, 2015, 10, e0130757.	1.1	17
78	Pilot study of liraglutide effects in nonâ€alcoholic steatohepatitis and nonâ€alcoholic fatty liver disease with glucose intolerance in <scp>J</scp>apanese patients (<scp>LEAN</scp>â€<scp>J</scp>). Hepatology Research, 2015, 45, 269-278.	1.8	148
79	Effect of Vildagliptin on Hepatic Steatosis. Journal of Clinical Endocrinology and Metabolism, 2015, 100, 1578-1585.	1.8	109
80	Effects of sitagliptin on ectopic fat contents and glucose metabolism in type 2 diabetic patients with fatty liver: A pilot study. Journal of Diabetes Investigation, 2015, 6, 164-172.	1.1	23
81	Control of liver glucokinase activity: A potential new target for incretin hormones?. Peptides, 2015, 74, 57-63.	1.2	7
82	Acarbose, lente carbohydrate, and prebiotics promote metabolic health and longevity by stimulating intestinal production of GLP-1. Open Heart, 2015, 2, e000205.	0.9	33
83	Effect of sitagliptin on intrahepatic lipid content and body fat in patients with type 2 diabetes. Diabetes Research and Clinical Practice, 2015, 109, 199-205.	1.1	52
84	Rhizoma Anemarrhenae extract ameliorates hyperglycemia and insulin resistance via activation of AMP-activated protein kinase in diabetic rodents. Journal of Ethnopharmacology, 2015, 172, 368-376.	2.0	27
85	Liraglutide improves carotid intima-media thickness in patients with type 2 diabetes and non-alcoholic fatty liver disease: an 8-month prospective pilot study. Expert Opinion on Biological Therapy, 2015, 15, 1391-1397.	1.4	36
86	Review on the effect of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors for the treatment of non-alcoholic fatty liver disease. Journal of Huazhong University of Science and Technology [Medical Sciences], 2015, 35, 333-336.	1.0	5
87	Exendin-4 regulates redox homeostasis in rats fed with high-fat diet. Acta Biochimica Et Biophysica Sinica, 2015, 47, 397-403.	0.9	16
88	Current efforts and trends in the treatment of NASH. Journal of Hepatology, 2015, 62, S65-S75.	1.8	228
89	Vascular AMPK as an attractive target in the treatment of vascular complications of obesity. Vascular Pharmacology, 2015, 67-69, 10-20.	1.0	23
90	Incretins. Handbook of Experimental Pharmacology, 2015, 233, 137-171.	0.9	45

#	Article	IF	Citations
91	Physiology of Proglucagon Peptides: Role of Glucagon and GLP-1 in Health and Disease. Physiological Reviews, 2015, 95, 513-548.	13.1	340
92	Effects of Insulin Glargine and Liraglutide Therapy on Liver Fat as Measured by Magnetic Resonance in Patients With Type 2 Diabetes: A Randomized Trial. Diabetes Care, 2015, 38, 1339-1346.	4.3	104
93	Acarbose: safe and effective for lowering postprandial hyperglycaemia and improving cardiovascular outcomes. Open Heart, 2015, 2, e000327.	0.9	141
94	Insulinâ€independent actions of glucagonâ€like peptideâ€1 in wethers. Animal Science Journal, 2015, 86, 385-391.	0.6	2
95	Postprandial Dysmetabolism and Oxidative Stress in Type 2 Diabetes: Pathogenetic Mechanisms and Therapeutic Strategies. Medicinal Research Reviews, 2015, 35, 968-1031.	5.0	43
96	Lipoprotein effects of incretin analogs and dipeptidyl peptidase 4 inhibitors. Clinical Lipidology, 2015, 10, 103-112.	0.4	12
97	Exendin-4 attenuates cardiac hypertrophy via AMPK/mTOR signaling pathway activation. Biochemical and Biophysical Research Communications, 2015, 468, 394-399.	1.0	36
98	Empagliflozin and linagliptin combination therapy for treatment of patients with type 2 diabetes mellitus. Expert Opinion on Pharmacotherapy, 2015, 16, 2819-2833.	0.9	20
99	Exenatide Activates the APPL1-AMPK-PPARÎ±Axis to Prevent Diabetic Cardiomyocyte Apoptosis. Journal of Diabetes Research, 2016, 2016, 1-10.	1.0	17
100	Pathophysiology of Non Alcoholic Fatty Liver Disease. International Journal of Molecular Sciences, 2016, 17, 2082.	1.8	126
101	A Metabolic Inhibitory Cocktail for Grave Cancers: Metformin, Pioglitazone and Lithium Combination in Treatment of Pancreatic Cancer and Glioblastoma Multiforme. Biochemical Genetics, 2016, 54, 573-618.	0.8	37
102	Glucagonâ€like peptideâ€1 preserves nonâ€alcoholic fatty liver disease through inhibition of the endoplasmic reticulum stressâ€associated pathway. Hepatology Research, 2016, 46, 343-353.	1.8	41
103	Gastric bypass surgery is protective from highâ€fat dietâ€induced nonâ€alcoholic fatty liver disease and hepatic endoplasmic reticulum stress. Acta Physiologica, 2016, 217, 141-151.	1.8	29
104	Gastrointestinal actions of glucagonâ€like peptideâ€1â€based therapies: glycaemic control beyond the pancreas. Diabetes, Obesity and Metabolism, 2016, 18, 224-235.	2.2	51
105	Purslane (Portulaca oleracea) Seed Consumption And Aerobic Training Improves Biomarkers Associated with Atherosclerosis in Women with Type 2 Diabetes (T2D). Scientific Reports, 2016, 6, 37819.	1.6	43
106	Hepatic functions of GLP-1 and its based drugs: current disputes and perspectives. American Journal of Physiology - Endocrinology and Metabolism, 2016, 311, E620-E627.	1.8	49
107	Novel Pharmacotherapy Options for NASH. Digestive Diseases and Sciences, 2016, 61, 1398-1405.	1.1	35
108	Targeting AMP Kinase in Myeloid Cells to Reduce Atherosclerosis. Diabetes, 2016, 65, 1493-1495.	0.3	2

#	Article	IF	Citations
109	The glucagon-like peptide-1 analogue exendin-4 reverses impaired intracellular Ca 2+ signalling in steatotic hepatocytes. Biochimica Et Biophysica Acta - Molecular Cell Research, 2016, 1863, 2135-2146.	1.9	36
110	Treatment of Nonalcoholic Fatty Liver Disease (NAFLD) in patients with Type 2 Diabetes Mellitus. Clinical Diabetes and Endocrinology, 2016, 2, 9.	1.3	45
111	Treatment of patients with type 2 diabetes and non-alcoholic fatty liver disease: current approaches and future directions. Diabetologia, 2016, 59, 1112-1120.	2.9	102
112	Nonalcoholic Fatty Liver Disease. Endocrinology and Metabolism Clinics of North America, 2016, 45, 765-781.	1.2	107
113	DPP-4 inhibitors in diabetic complications: role of DPP-4 beyond glucose control. Archives of Pharmacal Research, 2016, 39, 1114-1128.	2.7	44
114	Promising therapies for treatment of nonalcoholic steatohepatitis. Expert Opinion on Emerging Drugs, 2016, 21, 343-357.	1.0	28
115	Pathogenesis and novel treatment options for non-alcoholic steatohepatitis. The Lancet Gastroenterology and Hepatology, 2016, 1, 56-67.	3.7	152
116	Exenatide improves both hepatic and adipose tissue insulin resistance: A dynamic positron emission tomography study. Hepatology, 2016, 64, 2028-2037.	3.6	78
117	Glucagon-Like Peptide-1 and Its Class B G Proteinâ€“Coupled Receptors: A Long March to Therapeutic Successes. Pharmacological Reviews, 2016, 68, 954-1013.	7.1	252
119	Metabolomic profiling reveals differential effects of glucagonâ€like peptideâ€1 and insulin on nutrient partitioning in ovine liver. Animal Science Journal, 2016, 87, 1480-1489.	0.6	4
120	Pharmacological management of nonalcoholic fatty liver disease. Metabolism: Clinical and Experimental, 2016, 65, 1183-1195.	1.5	86
121	The role of the gut microbiota in NAFLD. Nature Reviews Gastroenterology and Hepatology, 2016, 13, 412-425.	8.2	728
122	Self-reported eating speed in relation to non-alcoholic fatty liver disease in adults. European Journal of Nutrition, 2016, 55, 327-333.	1.8	21
123	Circulating adiponectin levels in type 2 diabetes mellitus patients with or without non-alcoholic fatty liver disease: Results of a small, open-label, randomized controlled intervention trial in a subgroup receiving short-term exenatide. Diabetes Research and Clinical Practice, 2016, 113, 125-134.	1.1	17
124	Incretinâ€based therapies for the treatment of nonâ€alcoholic fatty liver disease: A systematic review and metaâ€analysis. Journal of Gastroenterology and Hepatology (Australia), 2016, 31, 23-31.	1.4	70
125	GLP-1 based therapies: clinical implications for gastroenterologists. Gut, 2016, 65, 702-711.	6.1	34
126	Mechanisms of Action of Liraglutide in Patients With Type 2 Diabetes Treated With High-Dose Insulin. Journal of Clinical Endocrinology and Metabolism, 2016, 101, 1798-1806.	1.8	40
127	Emerging Therapies for Nonalcoholic Fatty Liver Disease. Clinics in Liver Disease, 2016, 20, 365-385.	1.0	8

#	Article	IF	Citations
128	Time for Glucagon like peptide-1 receptor agonists treatment for patients with NAFLD?. Journal of Hepatology, 2016, 64, 262-264.	1.8	30
129	Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study. Lancet, The, 2016, 387, 679-690.	6.3	1,397
130	Glucagon-like peptide 1 decreases lipotoxicity in non-alcoholic steatohepatitis. Journal of Hepatology, 2016, 64, 399-408.	1.8	308
131	Effects of Sleeve Gastrectomy and Gastric Bypass on Postprandial Lipid Profile in Obese Type 2 Diabetic Patients: a 2-Year Follow-up. Obesity Surgery, 2016, 26, 1247-1253.	1.1	29
132	Practical prospects for boosting hepatic production of the â€œpro-longevityâ€•hormone FGF21. Hormone Molecular Biology and Clinical Investigation, 2017, 30, .	0.3	4
133	The protective effects of probiotic-fermented soymilk on high-fat diet-induced hyperlipidemia and liver injury. Journal of Functional Foods, 2017, 30, 220-227.	1.6	56
134	Synergistic effects of metformin with liraglutide against endothelial dysfunction through GLP-1 receptor and PKA signalling pathway. Scientific Reports, 2017, 7, 41085.	1.6	24
135	Combination therapy with <scp>GLP</scp>â€1 receptor agonist and <scp>SGLT2</scp> inhibitor. Diabetes, Obesity and Metabolism, 2017, 19, 1353-1362.	2.2	120
136	Comparative effects of liraglutide 3 mg vs structured lifestyle modification on body weight, liver fat and liver function in obese patients with nonâ€alcoholic fatty liver disease: A pilot randomized trial. Diabetes, Obesity and Metabolism, 2017, 19, 1814-1817.	2.2	71
137	A Novel Interacting Protein SERP1 Regulates the Nâ€Linked Glycosylation and Function of GLPâ€1 Receptor in the Liver. Journal of Cellular Biochemistry, 2017, 118, 3616-3626.	1.2	7
138	The anti-diabetic drug exenatide, a glucagon-like peptide-1 receptor agonist, counteracts hepatocarcinogenesis through cAMPâ€“PKAâ€“EGFRâ€“STAT3 axis. Oncogene, 2017, 36, 4135-4149.	2.6	32
139	Glucagon-like peptide-1 effects lipotoxic oxidative stress by regulating the expression of microRNAs. Biochemical and Biophysical Research Communications, 2017, 482, 1462-1468.	1.0	7
140	GLP-1 receptor independent pathways: emerging beneficial effects of GLP-1 breakdown products. Eating and Weight Disorders, 2017, 22, 231-240.	1.2	25
141	Hepatogenous diabetes: Is it time to separate it from type 2 diabetes?. Liver International, 2017, 37, 950-962.	1.9	55
142	Recombinant Incretin-Secreting Microbe Improves Metabolic Dysfunction in High-Fat Diet Fed Rodents. Scientific Reports, 2017, 7, 13523.	1.6	16
143	Glucagon-like Peptide-1 and the Central/Peripheral Nervous System: Crosstalk in Diabetes. Trends in Endocrinology and Metabolism, 2017, 28, 88-103.	3.1	88
144	The Benefit of Sleeve Gastrectomy in Obese Adolescents on Nonalcoholic Steatohepatitis and Hepatic Fibrosis. Journal of Pediatrics, 2017, 180, 31-37.e2.	0.9	95
145	A novel glucagonâ€like peptide 1/glucagon receptor dual agonist improves steatohepatitis and liver regeneration in mice. Hepatology, 2017, 65, 950-968.	3.6	67

#	Article	IF	Citations
146	Protein kinases: mechanisms and downstream targets in inflammation-mediated obesity and insulin resistance. Molecular and Cellular Biochemistry, 2017, 426, 27-45.	1.4	137
147	Human Chorionic Plate-Derived Mesenchymal Stem Cells Restore Hepatic Lipid Metabolism in a Rat Model of Bile Duct Ligation. Stem Cells International, 2017, 2017, 1-9.	1.2	9
148	Effects of ingredients of Korean brown rice cookies on attenuation of cholesterol level and oxidative stress in high-fat diet-fed mice. Nutrition Research and Practice, 2017, 11, 365.	0.7	2
149	Exenatide induces carcinoembryonic antigenâ€related cell adhesion molecule 1 expression to prevent hepatic steatosis. Hepatology Communications, 2018, 2, 35-47.	2.0	13
150	Misregulation of membrane trafficking processes in human nonalcoholic steatohepatitis. Journal of Biochemical and Molecular Toxicology, 2018, 32, e22035.	1.4	11
151	Central administration of coagonist of GLP-1 and glucagon receptors improves dyslipidemia. Biomedicine and Pharmacotherapy, 2018, 98, 364-371.	2.5	11
152	Gliptins Suppress Inflammatory Macrophage Activation to Mitigate Inflammation, Fibrosis, Oxidative Stress, and Vascular Dysfunction in Models of Nonalcoholic Steatohepatitis and Liver Fibrosis. Antioxidants and Redox Signaling, 2018, 28, 87-109.	2.5	56
153	Exendin-4, a glucagon-like peptide-1 receptor agonist downregulates hepatic receptor for advanced glycation end products in non-alcoholic steatohepatitis rat model. Archives of Physiology and Biochemistry, 2018, 124, 10-17.	1.0	6
154	Nonalcoholic Steatohepatitis (NASH) and Hepatic Fibrosis: Emerging Therapies. Annual Review of Pharmacology and Toxicology, 2018, 58, 649-662.	4.2	56
155	The Effects of Duodenojejunal Omega Switch in Combination with High-Fat Diet and Control Diet on Incretins, Body Weight, and Glucose Tolerance in Sprague-Dawley Rats. Obesity Surgery, 2018, 28, 748-759.	1.1	15
156	Lipotoxicity and the gut-liver axis in NASH pathogenesis. Journal of Hepatology, 2018, 68, 280-295.	1.8	566
157	Glucose-Lowering Agents in the Management of Nonalcoholic Fatty Liver Disease. Journal of Korean Diabetes, 2018, 19, 88.	0.1	1
158	Differential Effects of a Glucagon-Like Peptide 1 Receptor Agonist in Non-Alcoholic Fatty Liver Disease and in Response to Hepatectomy. Scientific Reports, 2018, 8, 16461.	1.6	12
159	Antidiabetic Drugs in NAFLD: The Accomplishment of Two Goals at Once?. Pharmaceuticals, 2018, 11, 121.	1.7	41
160	Efficacy of liraglutide in treating type 2 diabetes mellitus complicated with non-alcoholic fatty liver disease. Bioscience Reports, 2018, 38, .	1.1	48
161	Future Perspectives on GLP-1 Receptor Agonists and GLP-1/glucagon Receptor Co-agonists in the Treatment of NAFLD. Frontiers in Endocrinology, 2018, 9, 649.	1.5	65
162	Sodium butyrate reduces high-fat diet-induced non-alcoholic steatohepatitis through upregulation of hepatic GLP-1R expression. Experimental and Molecular Medicine, 2018, 50, 1-12.	3.2	113
163	Multiple target tissue effects of GLP-1 analogues on non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH). Pharmacological Research, 2018, 137, 219-229.	3.1	54

#	Article	IF	Citations
164	Determination of Key Active Components in Different Edible Oils Affecting Lipid Accumulation and Reactive Oxygen Species Production in HepG2 Cells. Journal of Agricultural and Food Chemistry, 2018, 66, 11943-11956.	2.4	29
165	AÂsystematic review of the present and future of non-alcoholic fatty liver disease. Clinical and Experimental Hepatology, 2018, 4, 165-174.	0.6	41
166	Gut adaptation after metabolic surgery and its influences on the brain, liver and cancer. Nature Reviews Gastroenterology and Hepatology, 2018, 15, 606-624.	8.2	69
167	Exenatide ameliorates hepatic steatosis and attenuates fat mass and FTO gene expression through PI3K signaling pathway in nonalcoholic fatty liver disease. Brazilian Journal of Medical and Biological Research, 2018, 51, e7299.	0.7	20
168	GLP-1 receptor agonists stimulate ANGPTL8 production through the PI3K/Akt pathway in a GLP-1 receptor-dependent manner. Peptides, 2018, 106, 83-90.	1.2	15
169	Molecular Basis of Liver Disease. , 2018, , 417-456.		0
170	Dulaglutide decreases plasma aminotransferases in people with Type 2 diabetes in a pattern consistent with liver fat reduction: a post hoc analysis of the <scp>AWARD</scp> programme. Diabetic Medicine, 2018, 35, 1434-1439.	1.2	59
171	Role of cAMP and phosphodiesterase signaling in liver health and disease. Cellular Signalling, 2018, 49, 105-115.	1.7	85
172	Liraglutide treatment improves postprandial lipid metabolism and cardiometabolic risk factors in humans with adequately controlled type 2 diabetes: A singleâ€centre randomized controlled study. Diabetes, Obesity and Metabolism, 2019, 21, 84-94.	2.2	78
173	mTOR Signaling in X/Aâ€Like Cells Contributes to Lipid Homeostasis in Mice. Hepatology, 2019, 69, 860-875.	3.6	11
174	From NASH to diabetes and from diabetes to NASH: Mechanisms and treatment options. JHEP Reports, 2019, 1, 312-328.	2.6	251
175	Ameliorative effect of Lactobacillus plantarum WW-fermented soy extract on rat fatty liver via the PPAR signaling pathway. Journal of Functional Foods, 2019, 60, 103439.	1.6	12
176	Hepatocyte-specific HIF-1Î± ablation improves obesity-induced glucose intolerance by reducing first-pass GLP-1 degradation. Science Advances, 2019, 5, eaaw4176.	4.7	20
177	Effects of liraglutide on lipolysis and the AC3/PKA/HSL pathway . Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy, 2019, Volume 12, 1697-1703.	1.1	17
178	Interactions between gut microbiota and non-alcoholic liver disease: The role of microbiota-derived metabolites. Pharmacological Research, 2019, 141, 521-529.	3.1	78
179	The Effects of Hypoglycemic Agents on Non-alcoholic Fatty Liver Disease: Focused on Sodium-Glucose Cotransporter 2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists. Journal of Obesity and Metabolic Syndrome, 2019, 28, 18-29.	1.5	14
180	Modulation of Diabetes by Natural Products and Medicinal Plants via Incretins. Planta Medica, 2019, 85, 825-839.	0.7	11
181	Epicardial adipose tissue GLP-1 receptor is associated with genes involved in fatty acid oxidation and white-to-brown fat differentiation: A target to modulate cardiovascular risk?. International Journal of Cardiology, 2019, 292, 218-224.	0.8	55

#	Article	IF	Citations
182	Association of moderately elevated trimethylamine N-oxide with cardiovascular risk: is TMAO serving as a marker for hepatic insulin resistance. Open Heart, 2019, 6, e000890.	0.9	30
183	Liver-derived fibroblast growth factor 21 mediates effects of glucagon-like peptide-1 in attenuating hepatic glucose output. EBioMedicine, 2019, 41, 73-84.	2.7	49
184	Contribution of the gut microbiota to the regulation of host metabolism and energy balance: a focus on the gutâ€“liver axis. Proceedings of the Nutrition Society, 2019, 78, 319-328.	0.4	84
185	Bariatric surgery in patients with non-alcoholic fatty liver disease - from pathophysiology to clinical effects. World Journal of Hepatology, 2019, 11, 138-149.	0.8	122
186	Randomized trial comparing effects of weight loss by liraglutide with lifestyle modification in nonâ€alcoholic fatty liver disease. Liver International, 2019, 39, 941-949.	1.9	67
187	Gut Microbiota-Derived Mediators as Potential Markers in Nonalcoholic Fatty Liver Disease. BioMed Research International, 2019, 2019, 1-10.	0.9	37
188	Liraglutide Improves Non-Alcoholic Fatty Liver Disease In Diabetic Mice By Modulating Inflammatory Signaling Pathways . Drug Design, Development and Therapy, 2019, Volume 13, 4065-4074.	2.0	23
189	Role of Probiotics in Non-alcoholic Fatty Liver Disease: Does Gut Microbiota Matter?. Nutrients, 2019, 11, 2837.	1.7	64
190	Validity of biopsy-based drug effects in a diet-induced obese mouse model of biopsy-confirmed NASH. BMC Gastroenterology, 2019, 19, 228.	0.8	11
191	Small metabolites, possible big changes: a microbiota-centered view of non-alcoholic fatty liver disease. Gut, 2019, 68, 359-370.	6.1	236
192	Liraglutide induces beige fat development and promotes mitochondrial function in diet induced obesity mice partially through AMPK-SIRT-1-PGC1-Î± cell signaling pathway. Endocrine, 2019, 64, 271-283.	1.1	37
193	Resveratrol protects against nonalcoholic fatty liver disease by improving lipid metabolism and redox homeostasis via the PPARÎ± pathway. Applied Physiology, Nutrition and Metabolism, 2020, 45, 227-239.	0.9	47
194	Non-alcoholic fatty liver diseases: from role of gut microbiota to microbial-based therapies. European Journal of Clinical Microbiology and Infectious Diseases, 2020, 39, 613-627.	1.3	33
195	Liraglutide or insulin glargine treatments improves hepatic fat in obese patients with type 2 diabetes and nonalcoholic fatty liver disease in twenty-six weeks: A randomized placebo-controlled trial. Diabetes Research and Clinical Practice, 2020, 170, 108487.	1.1	48
196	Efficacy of Glucagon-Like Peptide-1 Analogs in Nonalcoholic Fatty Liver Disease: A Systematic Review . Hepatic Medicine: Evidence and Research, 2020, Volume 12, 139-151.	0.9	13
197	Circulating glucagon-like peptide-1 level in patients with liver cirrhosis. Archives of Physiology and Biochemistry, 2023, 129, 373-378.	1.0	4
198	Glucagon-Like Peptide-1 Receptor Agonist Prevented the Progression of Hepatocellular Carcinoma in a Mouse Model of Nonalcoholic Steatohepatitis. International Journal of Molecular Sciences, 2020, 21, 5722.	1.8	27
199	GLP1 agonists beyond glycemic controlâ€”redefining their role. International Journal of Diabetes in Developing Countries, 2020, 40, 461-463.	0.3	4

#	Article	IF	Citations
200	Liver Steatosis, Gut-Liver Axis, Microbiome and Environmental Factors. A Never-Ending Bidirectional Cross-Talk. Journal of Clinical Medicine, 2020, 9, 2648.	1.0	93
201	Gut-Pancreas-Liver Axis as a Target for Treatment of NAFLD/NASH. International Journal of Molecular Sciences, 2020, 21, 5820.	1.8	38
202	The Role of Gut Microbiome-Targeted Therapy in Nonalcoholic Fatty Liver Disease. Current Hepatology Reports, 2020, 19, 420-428.	0.4	0
203	Glucagonâ€like peptideâ€1 receptor agonists (GLPâ€1 RAs) for the management of nonalcoholic fatty liver disease (NAFLD): A systematic review. Endocrinology, Diabetes and Metabolism, 2020, 3, e00163.	1.0	34
204	Selenium-enriched Bifidobacterium longum DD98 relieves metabolic alterations and liver injuries associated with obesity in high-fat diet-fed mice. Journal of Functional Foods, 2020, 72, 104051.	1.6	13
205	Glucagonâ€Like Peptideâ€1: Actions and Influence on Pancreatic Hormone Function. , 2020, 10, 577-595.		16
206	Effect of liraglutide therapy on serum fetuin A in patients with type 2 diabetes and non-alcoholic fatty liver disease. Clinics and Research in Hepatology and Gastroenterology, 2020, 44, 674-680.	0.7	40
207	Effects of Exenatide and Humalog Mix25 on Fat Distribution, Insulin Sensitivity, and Î²-Cell Function in Normal BMI Patients with Type 2 Diabetes and Visceral Adiposity. Journal of Diabetes Research, 2020, 2020, 1-11.	1.0	3
208	Exendin-4 restores airway mucus homeostasis through the GLP1R-PKA-PPARÎ³-FOXA2-phosphatase signaling. Mucosal Immunology, 2020, 13, 637-651.	2.7	20
209	Long-Lasting Exendin-4 Fusion Protein Improves Memory Deficits in High-Fat Diet/Streptozotocin-Induced Diabetic Mice. Pharmaceutics, 2020, 12, 159.	2.0	20
210	Alterations in the Liver Fat Fraction Features Examined by Magnetic Resonance Imaging Following Bariatric Surgery: a Self-Controlled Observational Study. Obesity Surgery, 2020, 30, 1917-1928.	1.1	7
211	Liraglutide ameliorates obesity-related nonalcoholic fatty liver disease by regulating Sestrin2-mediated Nrf2/HO-1 pathway. Biochemical and Biophysical Research Communications, 2020, 525, 895-901.	1.0	36
212	Emerging targets and potential therapeutic agents in non-alcoholic fatty liver disease treatment. European Journal of Medicinal Chemistry, 2020, 197, 112311.	2.6	10
213	The GLP-1R agonist liraglutide limits hepatic lipotoxicity and inflammatory response in mice fed a methionine-choline deficient diet. Translational Research, 2021, 227, 75-88.	2.2	61
214	Emerging role of protein kinases in diabetes mellitus: From mechanism to therapy. Advances in Protein Chemistry and Structural Biology, 2021, 124, 47-85.	1.0	4
215	Revisiting the Complexity of GLP-1 Action from Sites of Synthesis to Receptor Activation. Endocrine Reviews, 2021, 42, 101-132.	8.9	115
216	The mother relationship between insulin resistance and non-alcoholic steatohepatitis: Glucosinolates hydrolysis products as a promising insulin resistance-modulator and fatty liver-preventer. Life Sciences, 2021, 264, 118615.	2.0	2
217	Incretin Hormones in Obesity and Related Cardiometabolic Disorders: The Clinical Perspective. Nutrients, 2021, 13, 351.	1.7	28

#	Article	IF	Citations
218	Glucagon-Like Peptide-1 Receptor Agonists for Treatment of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis: An Updated Meta-Analysis of Randomized Controlled Trials. Metabolites, 2021, 11, 73.	1.3	145
219	Metformin Resensitizes Sorafenib-Resistant HCC Cells Through AMPK-Dependent Autophagy Activation. Frontiers in Cell and Developmental Biology, 2020, 8, 596655.	1.8	19
220	Metformin Resensitizes Sorafenib-Resistant HCC Cells Through AMPK-Dependent Autophagy Activation. Frontiers in Cell and Developmental Biology, 2021, 8, .	1.8	3
221	Gut microbiota and their metabolites in the progression of non-alcoholic fatty liver disease. Hepatoma Research, 2021, 2021, 11.	0.6	25
222	Dulaglutide Alone and in Combination with Empagliflozin Attenuate Inflammatory Pathways and Microbiome Dysbiosis in a Non-Diabetic Mouse Model of NASH. Biomedicines, 2021, 9, 353.	1.4	18
223	Role of 2â€‘series prostaglandins in the pathogenesis of type 2 diabetes mellitus and nonâ€‘alcoholic fatty liver disease (Review). International Journal of Molecular Medicine, 2021, 47, .	1.8	22
224	Glucagon-Like Peptide-1 Receptor Agonists for Non-Alcoholic Fatty Liver Disease in Type 2 Diabetes: A Meta-Analysis. Frontiers in Endocrinology, 2021, 12, 609110.	1.5	41
226	Influence of cardiometabolic comorbidities on myocardial function, infarction, and cardioprotection: Role of cardiac redox signaling. Free Radical Biology and Medicine, 2021, 166, 33-52.	1.3	28
227	Non-Alcoholic Fatty Liver Disease and Cardiovascular Comorbidities: Pathophysiological Links, Diagnosis, and Therapeutic Management. Diagnostics, 2021, 11, 689.	1.3	20
228	Beinaglutide shows significantly beneficial effects in diabetes/obesity-induced nonalcoholic steatohepatitis in ob/ob mouse model. Life Sciences, 2021, 270, 118966.	2.0	11
229	GLP-1 reduces the migration of hepatocellular carcinoma cells via suppression of the stress-activated protein kinase/c-Jun N-terminal kinase pathway. Archives of Biochemistry and Biophysics, 2021, 703, 108851.	1.4	3
230	Reassessment of Pioglitazone for Alzheimerâ€™s Disease. Frontiers in Neuroscience, 2021, 15, 666958.	1.4	30
231	Intestinal Dysbiosis and Non-Alcoholic Fatty Liver Disease. Biochemistry, 0, , .	0.8	4
232	Abnormal Metabolism in the Progression of Nonalcoholic Fatty Liver Disease to Hepatocellular Carcinoma: Mechanistic Insights to Chemoprevention. Cancers, 2021, 13, 3473.	1.7	12
233	Novel Antidiabetic Strategies and Diabetologists' Views in Nonalcoholic Steatohepatitis. Seminars in Liver Disease, 2021, , .	1.8	2
234	Crosstalk between betaâ€adrenergic and insulin signaling mediates mechanistic target of rapamycin hyperactivation in liver of highâ€fat dietâ€fed male mice. Physiological Reports, 2021, 9, e14958.	0.7	3
235	Glucagon-like peptide-1 attenuated carboxymethyl lysine induced neuronal apoptosis via peroxisome proliferation activated receptor-Î³. Aging, 2021, 13, 19013-19027.	1.4	6
236	Non-Alcoholic Fatty Liver Disease and Its Association With Diabetes Mellitus. Cureus, 2021, 13, e17321.	0.2	3

#	Article	IF	Citations
237	Hepatic and Extrahepatic Insulin Clearance in Mice with Double Deletion of Glucagon-Like Peptide-1 and Glucose-Dependent Insulinotropic Polypeptide Receptors. Biomedicines, 2021, 9, 973.	1.4	1
238	Beneficial effects of glucagon-like peptide 1 receptor agonists on glucose control, cardiovascular risk profile, and non-alcoholic fatty liver disease. An expert opinion of the Italian diabetes society. Nutrition, Metabolism and Cardiovascular Diseases, 2021, 31, 3257-3270.	1.1	7
239	Novel approaches to intervene gut microbiota in the treatment of chronic liver diseases. FASEB Journal, 2021, 35, e21871.	0.2	20
240	Evidence-based clinical practice guidelines for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis 2020. Journal of Gastroenterology, 2021, 56, 951-963.	2.3	114
241	Horizon scanning of therapeutic modalities for nonalcoholic steatohepatitis. Annals of Hepatology, 2021, 24, 100315.	0.6	5
242	Evidenceâ€based clinicalÂpractice guidelines for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis 2020. Hepatology Research, 2021, 51, 1013-1025.	1.8	58
243	The pathophysiology of gutâ€“liver connection. , 2021, , 97-122.		0
244	Lipolytic Postbiotic from Lactobacillus paracasei Manages Metabolic Syndrome in Albino Wistar Rats. Molecules, 2021, 26, 472.	1.7	24
245	The interplay between host cellular and gut microbial metabolism in NAFLD development and prevention. Journal of Applied Microbiology, 2021, 131, 564-582.	1.4	3
246	NAFLD and Insulin Resistance: A Multisystemic Disease. , 2020, , 49-71.		1
247	New therapeutic strategies in nonalcoholic fatty liver disease: a focus on promising drugs for nonalcoholic steatohepatitis. Pharmacological Reports, 2020, 72, 1-12.	1.5	68
248	Hormonal Regulation of Lipogenesis. Vitamins and Hormones, 2013, 91, 1-27.	0.7	15
249	Exendin-4 Improves Steatohepatitis by Increasing Sirt1 Expression in High-Fat Diet-Induced Obese C57BL/6J Mice. PLoS ONE, 2012, 7, e31394.	1.1	119
250	Improved Glycaemia Correlates with Liver Fat Reduction in Obese, Type 2 Diabetes, Patients Given Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists. PLoS ONE, 2012, 7, e50117.	1.1	191
251	Extended Exenatide Administration Enhances Lipid Metabolism and Exacerbates Pancreatic Injury in Mice on a High Fat, High Carbohydrate Diet. PLoS ONE, 2014, 9, e109477.	1.1	9
252	Impact of exenatide on mitochondrial lipid metabolism in mice with nonalcoholic steatohepatitis. Journal of Endocrinology, 2019, 241, 293-305.	1.2	25
254	Reduced miR-200b and miR-200c expression contributes to abnormal hepatic lipid accumulation by stimulating JUN expression and activating the transcription ofsrebp1. Oncotarget, 2016, 7, 36207-36219.	0.8	34
255	Classical and Innovative Insulin Sensitizing Drugs for the Prevention and Treatment of NAFLD. Current Pharmaceutical Design, 2013, 19, 5280-5296.	0.9	7

#	Article	IF	Citations
256	Fighting Diabetes Mellitus: Pharmacological and Non-pharmacological Approaches. Current Pharmaceutical Design, 2020, 26, 4992-5001.	0.9	11
257	Exenatide Prevents Diet-induced Hepatocellular Injury in A CEACAM1-Dependent Mechanism. Journal of Diabetes and Treatment, 2017, 2017, .	0.5	3
258	Exenatide improves hepatic steatosis by enhancing lipid use in adipose tissue in nondiabetic rats. World Journal of Gastroenterology, 2014, 20, 2653.	1.4	25
259	Incretin based therapies: A novel treatment approach for non-alcoholic fatty liver disease. World Journal of Gastroenterology, 2014, 20, 7356.	1.4	33
260	Translational approaches: from fatty liver to non-alcoholic steatohepatitis. World Journal of Gastroenterology, 2014, 20, 9038-49.	1.4	43
261	Potential roles of glucagon-like peptide-1-based therapies in treating non-alcoholic fatty liver disease. World Journal of Gastroenterology, 2014, 20, 9090-7.	1.4	36
262	Intestinal permeability in the pathogenesis of liver damage: From non-alcoholic fatty liver disease to liver transplantation. World Journal of Gastroenterology, 2019, 25, 4814-4834.	1.4	101
263	Metabolic inflammation as an instigator of fibrosis during non-alcoholic fatty liver disease. World Journal of Gastroenterology, 2020, 26, 1993-2011.	1.4	67
264	Adenosine monophosphate-activated protein kinase-based classification of diabetes pharmacotherapy. Journal of Postgraduate Medicine, 2017, 63, 114-121.	0.2	9
265	Nonalcoholic fatty liver disease and Type 2 diabetes mellitus. Indian Journal of Endocrinology and Metabolism, 2018, 22, 421.	0.2	116
266	Glucagon-like peptide-1 receptor agonists in non-alcoholic fatty liver disease: An update. World Journal of Hepatology, 2020, 12, 493-505.	0.8	23
267	Clinical implications, diagnosis, and management of diabetes in patients with chronic liver diseases. World Journal of Hepatology, 2020, 12, 533-557.	0.8	13
268	Regulation of Serum Lipid Profile, Glucose, Insulin, and Adiponectin in Obese Diabetic Women Under Diet Therapy: A Randomized Clinical Controlled Study. Iranian Red Crescent Medical Journal, 2016, 19, .	0.5	2
269	Gut Microbiota-Related Cellular and Molecular Mechanisms in the Progression of Nonalcoholic Fatty Liver Disease. Cells, 2021, 10, 2634.	1.8	13
270	Advances in Unhealthy Nutrition and Circadian Dysregulation in Pathophysiology of NAFLD. Frontiers in Clinical Diabetes and Healthcare, 2021, 2, .	0.3	1
271	Nutrigenomics of Neuradaptogen Amino-Acid-Therapy and Neurometabolic Optimizers: Overcoming carbohydrate bingeing and overeating through neurometabolic mechanisms. Functional Foods in Health and Disease, 2011, 1, 310.	0.3	0
272	Pharmacologic Therapy for Nonalcoholic Fatty Liver Disease. Korean Journal of Medicine, 2014, 86, 425.	0.1	1
273	Extrapancreatic Effect of Glucagon like Peptide-1. Korean Journal of Medicine, 2015, 89, 404-412.	0.1	0

#	Article	IF	Citations
274	Oxidative Stress in Nonalcoholic Steatohepatitis. , 2016, , 349-361.		0
275	Diagnosis and Treatment of Nonalcoholic Fatty Liver Disease (NAFLD) in Type 2 Diabetes. Contemporary Diabetes, 2018, , 47-69.	0.0	0
276	Pathogenetic substantiation of approaches
to the treatment of non-alcoholic fatty liver disease.. Klinicheskaia Meditsina, 2018, 95, 1077-1085.	0.2	0
277	DIABETES MELLITUS: THE MODERN STATE OF THE ISSUE (PART 2). Avicenna Bulletin, 2019, 21, 661-674.	0.0	0
278	Application prospects of glucagon-like peptide-1 receptor agonists in treatment of metabolic diseases. World Chinese Journal of Digestology, 2020, 28, 393-400.	0.0	0
279	THE EFFICACY AND SAFETY OF VILDAGLIPTIN TREATMENT FOR NONALCOHOLIC FATTY LIVER DISEASE IN TYPE 2 DIABETES MELLITUS. Cumhuriyet Medical Journal, 0, , .	0.1	1
280	Pharmacological Options for NASH. , 2020, , 309-327.		0
282	The Effect of Liraglutide on Epicardial Adipose Tissue in Type 2 Diabetes. Journal of Diabetes Research, 2021, 2021, 1-6.	1.0	7
283	Regulation and role of amp-activated protein kinase at the cellular level and relevance to diabetes mellitus. , 2022, 1, 18.		0
284	Gut Microbiota and Short Chain Fatty Acids: Implications in Glucose Homeostasis. International Journal of Molecular Sciences, 2022, 23, 1105.	1.8	215
285	Understanding the Role of the Gut Microbiome and Microbial Metabolites in Non-Alcoholic Fatty Liver Disease: Current Evidence and Perspectives. Biomolecules, 2022, 12, 56.	1.8	98
286	Intestinal Barrier and Permeability in Health, Obesity and NAFLD. Biomedicines, 2022, 10, 83.	1.4	71
287	Hepatic steatosis changes after early gastric cancer surgery. Kosin Medical Journal, 2022, 37, 68-74.	0.1	0
288	Review article: role of glucagonâ€like peptideâ€1 receptor agonists in nonâ€alcoholic steatohepatitis, obesity and diabetesâ€”what hepatologists need to know. Alimentary Pharmacology and Therapeutics, 2022, 55, 944-959.	1.9	17
289	Responsive oligochitosan nano-vesicles with ursodeoxycholic acid and exenatide for NAFLD synergistic therapy via SIRT1. Carbohydrate Polymers, 2022, 288, 119388.	5.1	7
290	GLP-1 mimetics as a potential therapy for nonalcoholic steatohepatitis. Acta Pharmacologica Sinica, 2022, 43, 1156-1166.	2.8	11
291	The Impact of Incretin-Based Medications on Lipid Metabolism. Journal of Diabetes Research, 2021, 2021, 1-10.	1.0	12
292	Efficacy of Sodium-Glucose Cotransporter 2 Inhibitors in Patients With Concurrent Type 2 Diabetes Mellitus and Non-Alcoholic Steatohepatitis: A Review of the Evidence. Frontiers in Endocrinology, 2021, 12, 768850.	1.5	11

#	Article	IF	Citations
293	Comparative Transcriptome Analysis Reveals That Exendin-4 Improves Steatosis in HepG2 Cells by Modulating Signaling Pathways Related to Lipid Metabolism. Biomedicines, 2022, 10, 1020.	1.4	5
294	A Novel Bacterium, Butyricimonas virosa, Preventing HFD-Induced Diabetes and Metabolic Disorders in Mice via GLP-1 Receptor. Frontiers in Microbiology, 2022, 13, .	1.5	17
295	Efficacy and safety of oral semaglutide in patients with nonâ€alcoholic fatty liver disease complicated by type 2 diabetes mellitus: A pilot study. JGH Open, 2022, 6, 503-511.	0.7	10
296	Potential Effect of DPP-4 Inhibitors Towards Hepatic Diseases and Associated Glucose Intolerance. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy, 0, Volume 15, 1845-1864.	1.1	6
297	Non-Alcoholic Fatty Liver Disease and Extrahepatic Cancers: A Wolf in Sheepâ€™s Clothing?. Current Oncology, 2022, 29, 4478-4510.	0.9	6
298	Exendin-4 Attenuates Hepatic Steatosis by Promoting the Autophagy-Lysosomal Pathway. BioMed Research International, 2022, 2022, 1-7.	0.9	2
299	Recovery of Bacteroides thetaiotaomicron ameliorates hepatic steatosis in experimental alcohol-related liver disease. Gut Microbes, 2022, 14, .	4.3	25
300	A potential link between plasma shortâ€chain fatty acids, TNFâ€Î± level and disease progression in nonâ€alcoholic fatty liver disease: A retrospective study. Experimental and Therapeutic Medicine, 2022, 24, .	0.8	12
301	The Effects of Probiotics, Prebiotics and Synbiotics in Non-Alcoholic Fat Liver Disease (NAFLD) and Non-Alcoholic Steatohepatitis (NASH): A Systematic Review. International Journal of Molecular Sciences, 2022, 23, 8805.	1.8	37
302	Deficiency of peroxisomal NUDT7 stimulates de novo lipogenesis in hepatocytes. IScience, 2022, 25, 105135.	1.9	3
303	Molecular mechanisms of metabolic associated fatty liver disease (MAFLD): functional analysis of lipid metabolism pathways. Clinical Science, 2022, 136, 1347-1366.	1.8	56
304	How Far beyond Diabetes Can the Benefits of Glucagon-like Peptide-1 Receptor Agonists Go? A Review of the Evidence on Their Effects on Hepatocellular Carcinoma. Cancers, 2022, 14, 4651.	1.7	14
305	Gut microbiome and microbial metabolites in NAFLD and after bariatric surgery: Correlation and causality. Frontiers in Microbiology, 0, 13, .	1.5	16
306	Prevalence and Specific Manifestations of Non-alcoholic Fatty Liver Disease (NAFLD) and Diabetes Mellitus Type 2 Association in a Moroccan Population: A Cross-sectional Study. Review of Diabetic Studies, 2022, 18, 140-145.	0.5	3
307	Semaglutide May Alleviate Hepatic Steatosis in T2DM Combined with NFALD Mice via miR-5120/ABHD6. Drug Design, Development and Therapy, 0, Volume 16, 3557-3572.	2.0	3
309	Glucagon-like peptide-1 receptor mediates the improvement in glycolipid metabolism disorder via AKT and AMPK signalling pathways in L02 cells with insulin resistance. Journal of Molecular Structure, 2023, 1273, 134328.	1.8	0
311	Clinical Impact of Glucagon-Like Peptide-1 Receptor Analogs on the Complications of Obesity. Obesity Facts, 2023, 16, 149-163.	1.6	4
312	Glucagon-Like Peptide-1 Receptor Agonists and Dual Glucose-Dependent Insulinotropic Polypeptide/Glucagon-Like Peptide-1 Receptor Agonists in the Treatment of Obesity/Metabolic Syndrome, Prediabetes/Diabetes and Non-Alcoholic Fatty Liver Diseaseâ€"Current Evidence. Journal of Cardiovascular Pharmacology and Therapeutics, 2022, 27, 10742484221114 63.	1.0	15

#	Article	IF	Citations
313	DoenÃ§a hepÃ¡tica gordurosa nÃ£o alcoÃ³lica, hormÃ´nios e exercÃÂcio fÃÂsico: uma abordagem fisiolÃ³gica. Revista Brasileira De Fisiologia Do ExercÃcio, 2018, 16, 304-318.	0.0	2
314	The effects of boronâ€supplemented diets on adipogenesisâ€related gene expressions, antiâ€inflammatory, and antioxidative response in highâ€fat fed rats. Journal of Biochemical and Molecular Toxicology, 2023, 37, .	1.4	4
315	Gut microbiota: The key to the treatment of metabolic syndrome in traditional Chinese medicine â€“ a case study of diabetes and nonalcoholic fatty liver disease. Frontiers in Immunology, 0, 13, .	2.2	2
316	Fat fighting liraglutide based nano-formulation to reverse obesity: Design, development and animal trials. International Journal of Pharmaceutics, 2023, 634, 122585.	2.6	3
317	GLP-1 Receptor Agonists in Non-Alcoholic Fatty Liver Disease: Current Evidence and Future Perspectives. International Journal of Molecular Sciences, 2023, 24, 1703.	1.8	31
318	An adipocentric perspective on the development and progression of non-alcoholic fatty liver disease. Journal of Hepatology, 2023, 78, 1048-1062.	1.8	35
319	Effects of overfeeding on liver lipid metabolism in mule ducks based on transcriptomics and metabolomics. British Poultry Science, 0, , .	0.8	0
320	GLP-1 analogues in the treatment of obesity and non-alcoholic fatty liver disease. Postepy Higieny I Medycyny Doswiadczalnej, 2023, 77, 1-8.	0.1	0
321	Resveratrol and Dulaglutide ameliorate adiposity and liver dysfunction in rats with diet-induced metabolic syndrome: Role of SIRT-1 / adipokines / PPARÎ³ and IGF-1. DARU, Journal of Pharmaceutical Sciences, 2023, 31, 13-27.	0.9	4
322	The Importance of Dietary Fiber for Metabolic Health. American Journal of Lifestyle Medicine, 0, , 155982762311677.	0.8	2
327	The intestine as an endocrine organ and the role of gut hormones in metabolic regulation. Nature Reviews Gastroenterology and Hepatology, 2023, 20, 784-796.	8.2	10
334	Gutâ€“brain communication mediates the impact of dietary lipids on cognitive capacity. Food and Function, 2024, 15, 1803-1824.	2.1	0